C Diff Drug Development

C Diff Drug Development

974 bookmarks
Custom sorting
Identification of Clostridium innocuum hypothetical protein that is cross-reactive with C. difficile anti-toxin antibodies - PubMed
Identification of Clostridium innocuum hypothetical protein that is cross-reactive with C. difficile anti-toxin antibodies - PubMed
Our findings do not suggest CI proteins CI_01448 and CI_01447, which cross-react with antibodies against CD toxins A and B, are toxic to HeLa cells. Further studies are needed to determine the function of these cross-reacting proteins and the potential virulence factors that could be responsible for …
·pubmed.ncbi.nlm.nih.gov·
Identification of Clostridium innocuum hypothetical protein that is cross-reactive with C. difficile anti-toxin antibodies - PubMed
Finch clips wings of hepatitis B program, hitting pause on clinical plan to focus on C. diff and autism - FierceBiotech
Finch clips wings of hepatitis B program, hitting pause on clinical plan to focus on C. diff and autism - FierceBiotech
Finch Therapeutics has joined the ranks of biotechs that are narrowing their focus. | Finch Therapeutics has joined the ranks of biotechs that are narrowing their focus. With its lead program under clinical hold, the microbiome specialist has pulled out of a planned study in chronic hepatitis B.
·fiercebiotech.com·
Finch clips wings of hepatitis B program, hitting pause on clinical plan to focus on C. diff and autism - FierceBiotech
Could Microbiome-Based Therapeutics Fill the Unmet Need in Recurrent Clostridioides Difficile (C. Diff) Treatment? Spherix Investigates - Benzinga
Could Microbiome-Based Therapeutics Fill the Unmet Need in Recurrent Clostridioides Difficile (C. Diff) Treatment? Spherix Investigates - Benzinga
While physicians express excitement surrounding products in the microbiome sector, current challenges with access to fecal microbiota transplants may translate into slow adoption EXTON, Pa., March 23, 2022 /PRNewswire/
·benzinga.com·
Could Microbiome-Based Therapeutics Fill the Unmet Need in Recurrent Clostridioides Difficile (C. Diff) Treatment? Spherix Investigates - Benzinga
A new report on the recurrent #Cdiff infection therapy RBX2660 from @ferring suggests the microbiome benefits of the therapy can last up to 2 years #IDtwitter
A new report on the recurrent #Cdiff infection therapy RBX2660 from @ferring suggests the microbiome benefits of the therapy can last up to 2 years #IDtwitter
A new report on the recurrent #Cdiff infection therapy RBX2660 from @ferring suggests the microbiome benefits of the therapy can last up to 2 years #IDtwitterhttps://t.co/ZrFCIBlyOF— Contagion (@Contagion_Live) March 22, 2022
·twitter.com·
A new report on the recurrent #Cdiff infection therapy RBX2660 from @ferring suggests the microbiome benefits of the therapy can last up to 2 years #IDtwitter
Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting - BioSpace
Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting - BioSpace
Seres Therapeutics, Inc. will present preclinical findings tomorrow at the European Bone Marrow Transplantation (EBMT) Annual Meeting.
·biospace.com·
Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting - BioSpace
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial
In this Phase 2 trial, RBX2660 was safe and effective for reducing rCDI recurrence as compared to a historical control group. Microbiome changes are consistent with restorative changes implicated in resisting C. difficile recurrence. Clinical Trials Registration NCT02589847 (10/28/2015).
·pubmed.ncbi.nlm.nih.gov·
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial
Phase 3 Trial Paused for CP101 in Recurrent C. difficle Infection - Pharmacy Times
Phase 3 Trial Paused for CP101 in Recurrent C. difficle Infection - Pharmacy Times
Finch was still able to continue dosing patients in its past-ongoing PRISM-EXT phase 2 open-label trial of CP101 in recurrent CDI, because the CP101 lots used for PRISM-EXT were manufactured from material donated prior to December 1, 2019.
·pharmacytimes.com·
Phase 3 Trial Paused for CP101 in Recurrent C. difficle Infection - Pharmacy Times
Selecta back in phase 1 gene therapy saddle after clinical hold lift, plans to reboot 'expeditiously' | Fierce Biotech
Selecta back in phase 1 gene therapy saddle after clinical hold lift, plans to reboot 'expeditiously' | Fierce Biotech
The FDA has lifted the clinical hold on Selecta Bioscience’s gene therapy to treat methylmalonic acidemia, a rare disease in children that affects metabolism. | The FDA has lifted the clinical hold on Selecta Bioscience’s gene therapy to treat methylmalonic acidemia, a rare disease in children that affects metabolism. The company is now back in the saddle as it preps for a phase 1 trial.
·fiercebiotech.com·
Selecta back in phase 1 gene therapy saddle after clinical hold lift, plans to reboot 'expeditiously' | Fierce Biotech
Clostridioides Difficile Vaccine Candidate Indicates Strong Potential Effect - Precision Vaccinations
Clostridioides Difficile Vaccine Candidate Indicates Strong Potential Effect - Precision Vaccinations
New York-based Pfizer Inc. announced results from the CLOVER pivotal Phase 3 study evaluating its Clostridioides difficile (C. difficile) vaccine candidate (PF-06425090) in the prevention of C. difficile infection (CDI). Initial analyses of two protocol-defined secondary endpoints indicated a highly favorable benefit in reducing CDI severity and 100% vaccine efficacy in preventing medically attended CDI. However, the trial did not meet its pre-specified primary endpoint of prevention of primary CDI.
·precisionvaccinations.com·
Clostridioides Difficile Vaccine Candidate Indicates Strong Potential Effect - Precision Vaccinations
Development of 1,2,4-Oxadiazole Antimicrobial Agents to Treat Enteric Pathogens within the Gastrointestinal Tract
Development of 1,2,4-Oxadiazole Antimicrobial Agents to Treat Enteric Pathogens within the Gastrointestinal Tract
Colonization of the gastrointestinal (GI) tract with pathogenic bacteria is an important risk factor for the development of certain potentially severe and life-threatening healthcare-associated infections, yet efforts to develop effective decolonization agents have been largely unsuccessful thus far …
·pubmed.ncbi.nlm.nih.gov·
Development of 1,2,4-Oxadiazole Antimicrobial Agents to Treat Enteric Pathogens within the Gastrointestinal Tract
UB scientist co-authors NEJM paper demonstrating how an oral microbiome therapy prevents recurrent C. difficile infections
UB scientist co-authors NEJM paper demonstrating how an oral microbiome therapy prevents recurrent C. difficile infections
People who develop colitis with the virulent bacterium C. difficile, usually after a course of antibiotics or chemotherapy, experience severe diarrhea, inflammation of the colon and abdominal pain. Each year, nearly half a million Americans suffer from it. About 1 in 6 will go on to experience a relapse, and sometimes it continues to recur. C. difficile infections (CDI) are responsible for approximately 20,000 deaths annually.
·wnypapers.com·
UB scientist co-authors NEJM paper demonstrating how an oral microbiome therapy prevents recurrent C. difficile infections
Disappointing: phase 3 trial of Pfizer's #Cdiff vaccine failed to meet its primary endpoint, with efficacy of 31% against first primary episode of #CDI (after 3 doses).
Disappointing: phase 3 trial of Pfizer's #Cdiff vaccine failed to meet its primary endpoint, with efficacy of 31% against first primary episode of #CDI (after 3 doses).
Disappointing: phase 3 trial of Pfizer's #Cdiff vaccine failed to meet its primary endpoint, with efficacy of 31% against first primary episode of #CDI (after 3 doses). https://t.co/wUK60eZmsZ— Tom Sandora (@tomsandora) March 2, 2022
·twitter.com·
Disappointing: phase 3 trial of Pfizer's #Cdiff vaccine failed to meet its primary endpoint, with efficacy of 31% against first primary episode of #CDI (after 3 doses).
Microbiome-Based Enema Effective for Recurrent C. difficile
Microbiome-Based Enema Effective for Recurrent C. difficile
A stool-based enema composed of a broad variety of microbes (RBX2660, Rebiotix/Ferring) was up to 84% effective in reducing recurrent emClostridioides difficile/em infection (rCDI) in a study of more than 720 adults with rCDI.
·generalsurgerynews.com·
Microbiome-Based Enema Effective for Recurrent C. difficile